COMBIVIR

Compare COMBIVIR  to:
Compare
Compare

Generic Name for COMBIVIR

Lamivudine 150mg, zidovudine 300mg; tabs.

Legal Classification:

Rx

Pharmacological Class for COMBIVIR

Nucleoside analogues (reverse transcriptase inhibitors).

Manufacturer of COMBIVIR

GlaxoSmithKline Pharmaceuticals

Indications for COMBIVIR

HIV infection.

Adult dose for COMBIVIR

1 tab twice daily. Hepatic or renal dysfunction (CrCl <50mL/min): not recommended.

Children's dosing for COMBIVIR

Not recommended.

Warnings/Precautions for COMBIVIR

Bone marrow depression. Anemia. Not for use with other lamivudine or zidovudine products. Hepatitis B (monitor for post-treatment exacerbation). Decompensated liver disease or risk factors for liver disease. Suspend if lactic acidosis or hepatotoxicity (e.g., hepatomegaly, steatosis) occurs. Women, obesity, prolonged nucleoside exposure: increased risk of toxicity. Monitor blood counts. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for COMBIVIR

See literature. Avoid concomitant other forms of zalcitabine, stavudine, doxorubicin, ribavirin. Bone marrow suppression increased by ganciclovir, interferon-alpha, cytotoxic drugs. TMP/SMX, atovaquone, fluconazole, methadone, probenecid, valproic acid, possibly others may affect lamivudine or zidovudine blood levels (clinical significance unknown); monitor. Triple therapy (once daily regimen) with abacavir + tenofovir or with didanosine + tenofovir: high rate of early viral non-response (see literature). Monitor for treatment-associated toxicities with interferon-alpha with or without ribavirin.

Adverse Reactions for COMBIVIR

Headache, GI upset, malaise, fatigue, nasal symptoms, cough, musculoskeletal pain, neuropathy, insomnia, fever/chills, dizziness, depression, rash, myalgia, arthralgia, lab abnormalities (neutropenia, severe anemia, thrombocytopenia, elevated ALT/AST, bilirubin or amylase), hyperglycemia, seizures, lactic acidosis, severe hepatomegaly with steatosis, fat redistribution, myopathy; pancreatitis (rare).

Notes for COMBIVIR

Register pregnant patients exposed to lamivudine by calling (800) 258-4263.

How is COMBIVIR supplied?

Tabs—60

Related Disease:

HIV~antivirals

Related Resources

Abbott RealTime HBV test approved

September 02, 2010

Abbott announced that the FDA has approved its RealTime HBV assay for measuring the amount of hepatitis B virus (HBV) in human plasma or serum from individuals chronically infected with HBV.

Longer use of Valcyte for renal transplant patients approved

August 11, 2010

The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.

Phase 3 study of boceprevir for the treatment of HCV

August 05, 2010

Merck announced the completion and results of its two Phase 3 studies for boceprevir for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.

Afluria labeling updated to include fever and febrile seizure risk

August 02, 2010

The Prescribing Information for Afluria (trivalent, inactivated, "split virus" influenza vaccine [Types A and B], from CSL Biotherapies) has been updated to inform healthcare professionals of an increased incidence of fever and febrile seizure among young children in Australia, mainly those <5years of age.

Fluzone available for 2010-2011 influenza season

July 30, 2010

Sanofi Pasteur announced that it has begun shipping the 2010-2011 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions